GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020
The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 3073766. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect. A webcast replay will be available via the “Investors” tab on the
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development of the Company’s product candidates, including expectations with regard to the enrollment of patients in its ongoing Phase 3 clinical trial of uproleselan and the Company’s engagement with regulatory authorities, as well as the presentation of data from preclinical studies and clinical trials and the potential benefits and impact of the Company’s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005292/en/
Investor:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: